Marshall Wace, LLP Sellas Life Sciences Group, Inc. Transaction History
Marshall Wace, LLP
- $81.7 Billion
- Q2 2025
A detailed history of Marshall Wace, LLP transactions in Sellas Life Sciences Group, Inc. stock. As of the latest transaction made, Marshall Wace, LLP holds 2,715,489 shares of SLS stock, worth $4.37 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
2,715,489
Previous 11,482
23549.97%
Holding current value
$4.37 Million
Previous $12,000
49450.0%
% of portfolio
0.01%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding SLS
# of Institutions
74Shares Held
25.3MCall Options Held
538KPut Options Held
26.3K-
Vanguard Group Inc Valley Forge, PA6.65MShares$10.7 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA2.2MShares$3.54 Million0.0% of portfolio
-
State Street Corp Boston, MA1.11MShares$1.79 Million0.0% of portfolio
-
Nuveen, LLC Charlotte, NC971KShares$1.56 Million0.0% of portfolio
-
Northern Trust Corp Chicago, IL698KShares$1.12 Million0.0% of portfolio
About SELLAS Life Sciences Group, Inc.
- Ticker SLS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 20,551,900
- Market Cap $33.1M
- Description
- SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the tr...